Akero Therapeutics Inc.

Contributing Author

Recent Articles by Akero Therapeutics Inc.

May-12	Akero Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update AKRO GlobeNewswire
May-10	Akero Therapeutics and HistoIndex Present New Analyses of Phase 2b HARMONY Trial in Oral and Poster Presentations at the EASL Congress 2025 AKRO GlobeNewswire
May-09	Akero Therapeutics Presents Week 96 Results from Phase 2b SYMMETRY Clinical Trial of Efruxifermin in Patients with Compensated Cirrhosis Caused by MASH Showing Fibrosis Improvement without Worsening of MASH at the EASL Congress 2025 AKRO GlobeNewswire
May-09	Akero Therapeutics Announces Publication of Phase 2b SYMMETRY Trial in the New England Journal of Medicine AKRO GlobeNewswire
May-09	Akero Therapeutics Presents Week 96 Results from Phase 2b SYMMETRY Clinical Trial of Efruxifermin in Patients with Compensated Cirrhosis Caused by MASH Showing Fibrosis Improvement without Worsening of MASH at the EASL Congress 2025 AKRO GlobeNewswire
May-07	Akero Therapeutics to Present at the BofA Securities 2025 Healthcare Conference AKRO GlobeNewswire